{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:39:32Z","timestamp":1790710772452,"version":"4.1.0"},"reference-count":245,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH356"],"award-info":[{"award-number":["ZR2023QH356"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pscia.2026.100109","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:32:20Z","timestamp":1770683540000},"page":"100109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy"],"prefix":"10.1016","volume":"4","author":[{"given":"Rulin","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deping","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5260-7783","authenticated-orcid":false,"given":"Liwei","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s13045-020-00998-9","article-title":"Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy","volume":"13","author":"Yilmaz","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-023-00982-7","article-title":"New immune cell engagers for cancer immunotherapy","volume":"24","author":"Fenis","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib3","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3389\/fimmu.2019.01415","article-title":"An historical overview: the discovery of how NK cells can kill enemies, recruit defense troops, and more","volume":"10","author":"Vitale","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib4","first-page":"1","article-title":"NK cell receptors","author":"Tian","year":"2015","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.115122","article-title":"Overcoming CD226-related immune evasion in acute myeloid leukemia with CD38 CAR-engineered NK cells","volume":"44","author":"Melo Garcia","year":"2025","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","article-title":"Natural killer group 2D receptor and its ligands in cancer immune escape","volume":"18","author":"Duan","year":"2019","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib7","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1084\/jem.190.10.1505","article-title":"Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells","volume":"190","author":"Pende","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pscia.2026.100109_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/1471-2407-9-186","article-title":"Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions","volume":"9","author":"Garcia-Iglesias","year":"2009","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib9","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1084\/jem.186.3.353","article-title":"Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene","volume":"186","author":"Johansson","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.pscia.2026.100109_bib10","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/cmi.2013.10","article-title":"NK cell-based immunotherapy for malignant diseases","volume":"10","author":"Cheng","year":"2013","journal-title":"Cell. Mol. Immunol."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.cmet.2018.06.021","article-title":"Dysfunction of natural killer cells by FBP1-induced inhibition of glycolysis during lung cancer progression","volume":"28","author":"Cong","year":"2018","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.pscia.2026.100109_bib14","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/ni.3800","article-title":"Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells","volume":"18","author":"Gao","year":"2017","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.pscia.2026.100109_bib15","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1016\/j.ymthe.2018.06.016","article-title":"Combination of asiatic acid and naringenin modulates NK cell anti-cancer immunity by rebalancing Smad3\/Smad7 signaling","volume":"26","author":"Lian","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.pscia.2026.100109_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14677","article-title":"Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development","volume":"8","author":"Tang","year":"2017","journal-title":"Nat. Commun."},{"issue":"415","key":"10.1016\/j.pscia.2026.100109_bib17","doi-asserted-by":"crossref","first-page":"ra19","DOI":"10.1126\/scisignal.aad1884","article-title":"TGF-\u03b2 inhibits the activation and functions of NK cells by repressing the mTOR pathway","volume":"9","author":"Viel","year":"2016","journal-title":"Sci. Signal."},{"key":"10.1016\/j.pscia.2026.100109_bib18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3389\/fimmu.2015.00543","article-title":"Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-Inhibited NK cells in HNSCC tumor spheroids","volume":"6","author":"Kl\u00f6ss","year":"2015","journal-title":"Front. Immunol."},{"issue":"26","key":"10.1016\/j.pscia.2026.100109_bib19","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2022015474","article-title":"GARP-mediated active TGF-\u03b21 induces bone marrow NK cell dysfunction in AML patients with early relapse post-allo-HSCT","volume":"140","author":"Wang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2026.100109_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275904","article-title":"Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy","volume":"14","author":"Fantini","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib21","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/s41467-024-55788-5","article-title":"NPC1 controls TGFBR1 stability in a cholesterol transport-independent manner and promotes hepatocellular carcinoma progression","volume":"16","author":"Li","year":"2025","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib22","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.4049\/jimmunol.1302389","article-title":"NK cells are the crucial antitumor mediators when STAT3-mediated immunosuppression is blocked in hepatocellular carcinoma","volume":"193","author":"Sui","year":"2014","journal-title":"J. Immunol."},{"issue":"5-6","key":"10.1016\/j.pscia.2026.100109_bib23","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/08977194.2022.2124915","article-title":"Increased circulating TGF-\u03b21 is associated with impairment in NK cell effector functions in metastatic melanoma patients","volume":"40","author":"Mirja\u010di\u0107 Martinovi\u0107","year":"2022","journal-title":"Growth Factors"},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib24","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.3892\/or.2012.1984","article-title":"Downregulation of indoleamine-2,3-dioxygenase in cervical cancer cells suppresses tumor growth by promoting natural killer cell accumulation","volume":"28","author":"Sato","year":"2012","journal-title":"Oncol. Rep."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib25","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib26","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.29481","article-title":"Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients","volume":"137","author":"Jia","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s12967-022-03554-w","article-title":"IDO\/kynurenine pathway in cancer: possible therapeutic approaches","volume":"20","author":"Abd El-Fattah","year":"2022","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib28","doi-asserted-by":"crossref","first-page":"6511","DOI":"10.1007\/s13277-014-1859-3","article-title":"IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis","volume":"35","author":"Isla Larrain","year":"2014","journal-title":"Tumour Biol"},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib29","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.pscia.2026.100109_bib30","article-title":"mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity","volume":"5","author":"Kenney","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"12","key":"10.1016\/j.pscia.2026.100109_bib31","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1016\/j.celrep.2017.08.089","article-title":"Tumor-derived mesenchymal stem cells use distinct mechanisms to block the activity of natural killer cell subsets","volume":"20","author":"Galland","year":"2017","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib32","doi-asserted-by":"crossref","first-page":"974","DOI":"10.4161\/onci.20405","article-title":"How melanoma cells inactivate NK cells","volume":"1","author":"Pietra","year":"2012","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib33","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.canlet.2011.12.020","article-title":"Hepatocellular carcinoma-associated fibroblasts trigger NK cell dysfunction via PGE2 and IDO","volume":"318","author":"Li","year":"2012","journal-title":"Cancer Lett."},{"issue":"6621","key":"10.1016\/j.pscia.2026.100109_bib34","doi-asserted-by":"crossref","first-page":"eabl7207","DOI":"10.1126\/science.abl7207","article-title":"Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion","volume":"378","author":"Zeng","year":"2022","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib35","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"27","key":"10.1016\/j.pscia.2026.100109_bib36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2302534120","article-title":"Antisense oligonucleotide rescue of CGG expansion-dependent FMR1 mis-splicing in fragile X syndrome restores FMRP","volume":"120","author":"Shah","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113388","article-title":"PTIR1 acts as an isoform of DDX58 and promotes tumor immune resistance through activation of UCHL5","volume":"42","author":"Song","year":"2023","journal-title":"Cell Rep."},{"issue":"18","key":"10.1016\/j.pscia.2026.100109_bib38","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.3390\/cancers15184616","article-title":"Dysregulation of DNAM-1-mediated NK cell anti-cancer responses in the tumor microenvironment","volume":"15","author":"Paolini","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.pscia.2026.100109_bib39","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.3390\/ijms20153715","article-title":"DNAM-1 activating receptor and its ligands: how do viruses affect the NK cell-mediated immune surveillance during the various phases of infection?","volume":"20","author":"Cifaldi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pscia.2026.100109_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/6248590","article-title":"Altered NKp30, NKp46, NKG2D, and DNAM-1 expression on circulating NK cells is associated with tumor progression in human gastric cancer","author":"Han","year":"2018","journal-title":"J. Immunol. Res."},{"issue":"16","key":"10.1016\/j.pscia.2026.100109_bib41","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1158\/0008-5472.CAN-10-4179","article-title":"Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma","volume":"71","author":"Platonova","year":"2011","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib42","doi-asserted-by":"crossref","first-page":"836","DOI":"10.3324\/haematol.2013.087536","article-title":"Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia","volume":"99","author":"Stringaris","year":"2014","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib43","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1264562","article-title":"High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer","volume":"6","author":"Sun","year":"2016","journal-title":"OncoImmunology"},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib44","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.pscia.2026.100109_bib45","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Keir","year":"2008","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2024.114867","article-title":"Developing enhanced immunotherapy using NKG2A knockout human pluripotent stem cell-derived NK cells","volume":"43","author":"Qin","year":"2024","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jaci.2016.04.025","article-title":"Identification of a subset of human natural killer cells expressing high levels of programmed death 1: a phenotypic and functional characterization","volume":"139","author":"Pesce","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib48","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2010894","article-title":"Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma","volume":"11","author":"Shao","year":"2022","journal-title":"OncoImmunology"},{"key":"10.1016\/j.pscia.2026.100109_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.smim.2017.08.003","article-title":"Natural killer cell immunotherapies against cancer: checkpoint inhibitors and more","volume":"31","author":"Chiossone","year":"2017","journal-title":"Semin. Immunol."},{"issue":"45","key":"10.1016\/j.pscia.2026.100109_bib50","doi-asserted-by":"crossref","first-page":"72961","DOI":"10.18632\/oncotarget.12150","article-title":"PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma","volume":"7","author":"Beldi-Ferchiou","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib51","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1158\/2326-6066.CIR-13-0171","article-title":"Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade","volume":"2","author":"Ines Pires da Silva","year":"2014","journal-title":"Cancer Immunol. Res."},{"issue":"15","key":"10.1016\/j.pscia.2026.100109_bib52","doi-asserted-by":"crossref","first-page":"eabj3286","DOI":"10.1126\/sciadv.abj3286","article-title":"When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer","volume":"8","author":"Hasim","year":"2022","journal-title":"Sci. Adv."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib53","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3109\/08820139.2015.1052145","article-title":"The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer","volume":"44","author":"Wang","year":"2015","journal-title":"Immunol. Investig."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.3109\/08820139.2015.1052145","article-title":"The clinical significance of abnormal Tim-3 expression on NK cells from patients with gastric cancer","volume":"44","author":"Wang","year":"2015","journal-title":"Immunol. Investig."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib55","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/0008-5472.CAN-19-2332","article-title":"Tim-3 hampers tumor surveillance of liver-resident and conventional NK cells by disrupting PI3K signaling","volume":"80","author":"Tan","year":"2020","journal-title":"Cancer Res."},{"issue":"21","key":"10.1016\/j.pscia.2026.100109_bib56","doi-asserted-by":"crossref","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","article-title":"Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy","volume":"22","author":"Blake","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"101","key":"10.1016\/j.pscia.2026.100109_bib57","doi-asserted-by":"crossref","first-page":"eadp7302","DOI":"10.1126\/sciimmunol.adp7302","article-title":"Palmitoylation of TIM-3 promotes immune exhaustion and restrains antitumor immunity","volume":"9","author":"Zhang","year":"2024","journal-title":"Sci. Immunol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib58","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/ni.2850","article-title":"The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions","volume":"15","author":"Chan","year":"2014","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib59","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nri3799","article-title":"Balancing natural killer cell activation through paired receptors","volume":"15","author":"Martinet","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib60","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41590-018-0132-0","article-title":"Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity","volume":"19","author":"Zhang","year":"2018","journal-title":"Nat. Immunol."},{"issue":"19","key":"10.1016\/j.pscia.2026.100109_bib61","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1158\/0008-5472.CAN-16-0839","article-title":"Adaptive NK cells with low TIGIT expression are inherently resistant to myeloid-derived suppressor cells","volume":"76","author":"Sarhan","year":"2016","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib62","doi-asserted-by":"crossref","DOI":"10.1080\/16078454.2023.2166333","article-title":"Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT\/CD155 pathway","volume":"28","author":"Yue","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib63","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/hep.30347","article-title":"Human CD96 correlates to natural killer cell exhaustion and predicts the prognosis of human hepatocellular carcinoma","volume":"70","author":"Sun","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pscia.2026.100109_bib64","unstructured":"Smith J, Johnson A, Brown R, Garcia M, Davis S, Miller C, et al. Preclinical development of BMS-986442, a novel Fc-enhanced bispecific antibody targeting TIGIT and CD96 for cancer immunotherapy. Poster Presented at: American Association for Cancer Research Annual Meeting; April 5-10, 2024; San Diego, CA. Abstract 3915."},{"key":"10.1016\/j.pscia.2026.100109_bib65","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.3389\/fimmu.2019.03010","article-title":"Recalling the biological significance of immune checkpoints on NK cells: a chance to overcome LAG3, PD1, and CTLA4 inhibitory pathways by adoptive NK cell transfer?","volume":"10","author":"Lanuza","year":"2020","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.pscia.2026.100109_bib66","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with Relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-B","year":"2021","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib67","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3390\/cancers13030426","article-title":"Activated lymphocytes and increased risk of dermatologic adverse events during Sorafenib therapy for hepatocellular carcinoma","volume":"13","author":"Corominas","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"6024","key":"10.1016\/j.pscia.2026.100109_bib68","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pscia.2026.100109_bib69","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.cell.2025.02.014","article-title":"Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs","volume":"188","author":"Jiang","year":"2025","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib70","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011652","article-title":"Therapeutic potential of targeting LAG-3 in cancer","volume":"13","author":"Davar","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib71","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13045-025-01669-3","article-title":"First-in-human evaluation of memory-like NK cells with an IL-15 super-agonist and CTLA-4 blockade in advanced head and neck cancer","volume":"18","author":"Shapiro","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.pscia.2026.100109_bib72","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2051-1426-1-10","article-title":"Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer","volume":"1","author":"Wesolowski","year":"2013","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib73","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41467-023-44391-9","article-title":"FOXP3+ regulatory T cell perturbation mediated by the IFN\u03b3-STAT1-IFITM3 feedback loop is essential for anti-tumor immunity","volume":"15","author":"Liu","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pscia.2026.100109_bib74","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3389\/fimmu.2018.00398","article-title":"Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression","volume":"9","author":"Fleming","year":"2018","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib75","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-017-0308-4","article-title":"Inhibition of arginase by CB-1158 blocks myeloid cell-mediated immune suppression in the tumor microenvironment","volume":"5","author":"Steggerda","year":"2017","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib76","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat. Rev. Immunol."},{"issue":"7980","key":"10.1016\/j.pscia.2026.100109_bib77","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41586-023-06511-9","article-title":"CD300ld on neutrophils is required for tumour-driven immune suppression","volume":"621","author":"Wang","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib78","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41420-025-02627-1","article-title":"MARCO expression on myeloid-derived suppressor cells is essential for their differentiation and immunosuppression","volume":"11","author":"Liu","year":"2025","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib79","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","article-title":"Tumor-associated macrophages: from mechanisms to therapy","volume":"41","author":"Noy","year":"2014","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib80","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"Leukoc Biol"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cmi.2014.83","article-title":"The origin and function of tumor-associated macrophages","volume":"12","author":"Liu","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112406","article-title":"Tumor-associated macrophages derived exosomes; from pathogenesis to therapeutic opportunities","volume":"136","author":"Hadad","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib83","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/hep.26192","article-title":"Monocyte\/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48\/2B4 interactions","volume":"57","author":"Wu","year":"2013","journal-title":"Hepatology"},{"issue":"18","key":"10.1016\/j.pscia.2026.100109_bib84","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1182\/blood.2022015646","article-title":"Genome-wide CRISPR screens identify CD48 defining susceptibility to NK cytotoxicity in peripheral T-cell lymphomas","volume":"140","author":"Chiba","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib85","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/0008-5472.CAN-17-2719","article-title":"Tumor-derived TGF\u03b2 alters the ability of plasmacytoid dendritic cells to respond to innate immune signaling","volume":"78","author":"Terra","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib86","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41590-023-01475-4","article-title":"TREM2 macrophages drive NK cell paucity and dysfunction in lung cancer","volume":"24","author":"Park","year":"2023","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib87","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2011.04421.x","article-title":"\u03b1-Fetoprotein impairs activation of natural killer cells by inhibiting the function of dendritic cells","volume":"165","author":"Yamamoto","year":"2011","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib88","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.canlet.2015.09.017","article-title":"TLR7\/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma","volume":"369","author":"Zhou","year":"2015","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib89","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12943-020-01238-x","article-title":"Natural killer cells in cancer biology and therapy","volume":"19","author":"Wu","year":"2020","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib90","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-024-00743-1","article-title":"Macrophages and T cells in metabolic disorder-associated cancers","volume":"24","author":"Taranto","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib91","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fimmu.2020.00202","article-title":"Glycolysis and oxidative phosphorylation play critical roles in natural killer cell receptor-mediated natural killer cell functions","volume":"11","author":"Wang","year":"2020","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1158\/2326-6066.CIR-18-0481","article-title":"Lactate-mediated acidification of tumor microenvironment induces apoptosis of liver-resident NK cells in colorectal liver metastasis","volume":"7","author":"Harmon","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib93","first-page":"1954","article-title":"Activation-specific metabolic requirements for NK cell IFN-\u03b3 production","volume":"194","author":"Keppel","year":"2015","journal-title":"Immunol. Ser."},{"issue":"23","key":"10.1016\/j.pscia.2026.100109_bib94","article-title":"Glycolytic requirement for NK cell cytotoxicity and cytomegalovirus control","volume":"2","author":"Mah","year":"2017","journal-title":"CIO Insight"},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib95","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.celrep.2019.10.050","article-title":"Hypoxia regulates lymphoid development of human hematopoietic progenitors","volume":"29","author":"Chabi","year":"2019","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib96","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","article-title":"Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1\u03b1 unleashes NK cell activity","volume":"52","author":"Ni","year":"2020","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib97","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/eji.201343448","article-title":"Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC","volume":"43","author":"Balsamo","year":"2013","journal-title":"Eur. J. Immunol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib98","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/2326-6066.CIR-16-0129-T","article-title":"RIG-I resists hypoxia-induced immunosuppression and dedifferentiation","volume":"5","author":"Engel","year":"2017","journal-title":"Cancer Immunol. Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib99","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1186\/s12967-024-05033-w","article-title":"Advances in metabolic reprogramming of NK cells in the tumor microenvironment on the impact of NK therapy","volume":"22","author":"Miao","year":"2024","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib100","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13046-023-02629-w","article-title":"L-kynurenine induces NK cell loss in gastric cancer microenvironment via promoting ferroptosis","volume":"42","author":"Cui","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib101","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.cell.2016.01.043","article-title":"Communication by extracellular vesicles: where we are and where we need to go","volume":"164","author":"Tkach","year":"2016","journal-title":"Cell"},{"issue":"1737","key":"10.1016\/j.pscia.2026.100109_bib102","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0488","article-title":"Role for extracellular vesicles in the tumour microenvironment","volume":"373","author":"O'Loghlen","year":"2018","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib103","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1002\/cncr.34576","article-title":"Baseline extracellular vesicle TGF-\u03b2 is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer","volume":"129","author":"de Miguel-Perez","year":"2023","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib104","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3892\/ol.2015.3841","article-title":"Immunosuppression of breast cancer cells mediated by transforming growth factor-\u03b2 in exosomes from cancer cells","volume":"11","author":"Rong","year":"2016","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1042\/BST20120265","article-title":"Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes)","volume":"41","author":"Whiteside","year":"2013","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.pscia.2026.100109_bib106","article-title":"Increased peritoneal TGF-\u03b21 is associated with ascites-induced NK-cell dysfunction and reduced survival in high-grade epithelial ovarian cancer","volume":"15","author":"Maas","year":"2024","journal-title":"Front Imunol"},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib107","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/cancers11060874","article-title":"Tumor-derived eextracellular vesicles inhibit natural killer cell function in pancreatic cancer","volume":"11","author":"Zhao","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib108","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1062968","article-title":"Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-\u03b2 and miR23a transfer","volume":"5","author":"Berchem","year":"2015","journal-title":"OncoImmunology"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib109","first-page":"134","article-title":"Loss of FBP1 facilitates aggressive features of hepatocellular carcinoma cells through the Warburg effect","volume":"38","author":"Yang","year":"2017","journal-title":"Carcinogenesis"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ymthe.2021.07.015","article-title":"Extracellular vesicle-mediated communication between hepatocytes and natural killer cells promotes hepatocellular tumorigenesis","volume":"30","author":"Liu","year":"2022","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib111","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-023-01384-w","article-title":"Colorectal cancer-derived extracellular vesicles induce liver premetastatic immunosuppressive niche formation to promote tumor early liver metastasis","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib112a","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-021-01492-7","article-title":"Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy","volume":"21","author":"Hosseini","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib112b","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3389\/fimmu.2019.01242","article-title":"PD1-PD-Ls checkpoint: insight on the potential role of NK cells","volume":"10","author":"Pesce","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib113","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib114","doi-asserted-by":"crossref","DOI":"10.1080\/15592294.2025.2509044","article-title":"PRMT1 promotes immune escape in hepatocellular carcinoma by regulating arginine methylation modification of MYC protein","volume":"20","author":"Zhou","year":"2025","journal-title":"Epigenetics"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s42003-025-08031-w","article-title":"HKDC1 promotes ovarian cancer progression through boosting lipid metabolism and immune escape by stabilizing G6PC\/G6PC2","volume":"8","author":"Wang","year":"2025","journal-title":"Commun. Biol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib116","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.7150\/thno.103494","article-title":"OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I","volume":"15","author":"Xing","year":"2025","journal-title":"Theranostics"},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib117","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.4049\/jimmunol.1501982","article-title":"NKG2D-NKG2D ligand interaction inhibits the outgrowth of naturally arising low-grade B cell lymphoma in vivo","volume":"196","author":"Raju","year":"2016","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib118","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.4049\/jimmunol.1100413","article-title":"Cancer immunoediting of the NK group 2D ligand H60a","volume":"187","author":"O'Sullivan","year":"2011","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib119","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41423-025-01297-4","article-title":"Adjusting the scope of natural killer cells in cancer therapy","volume":"22","author":"Shen","year":"2025","journal-title":"Cell. Mol. Immunol."},{"issue":"14","key":"10.1016\/j.pscia.2026.100109_bib120","doi-asserted-by":"crossref","first-page":"3684","DOI":"10.1158\/0008-5472.CAN-13-3021","article-title":"Ly49 family receptors are required for cancer immunosurveillance mediated by natural killer cells","volume":"74","author":"Tu","year":"2014","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib121","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/JLB.2MR0820-652R","article-title":"Escape of tumor cells from the NK cell cytotoxic activity","volume":"108","author":"Cantoni","year":"2020","journal-title":"J. Leukoc. Biol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib122","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1016\/j.celrep.2019.10.093","article-title":"A tumor-specific super-enhancer drives immune evasion by guiding synchronous expression of PD-L1 and PD-L2","volume":"29","author":"Xu","year":"2019","journal-title":"Cell Rep."},{"issue":"12","key":"10.1016\/j.pscia.2026.100109_bib123","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1078-0432.CCR-16-1761","article-title":"PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer","volume":"23","author":"Yearley","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.pscia.2026.100109_bib124","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib125","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41590-025-02137-3","article-title":"IL-10 targets IRF transcription factors to suppress IFN and inflammatory response genes by epigenetic mechanisms","volume":"26","author":"Mishra","year":"2025","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib126","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2023.12.015","article-title":"IL-10 dampens antitumor immunity and promotes liver metastasis via PD-L1 induction","volume":"80","author":"Shiri","year":"2024","journal-title":"J. Hepatol."},{"issue":"47","key":"10.1016\/j.pscia.2026.100109_bib127","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213835119","article-title":"Somatic 9p24.1 alterations in HPV- head and neck squamous cancer dictate immune microenvironment and anti-PD-1 checkpoint inhibitor activity","volume":"119","author":"Zhao","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib128","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41467-018-03584-3","article-title":"Oncofetal gene SALL4 reactivation by hepatitis B virus counteracts miR-200c in PD-L1-induced T cell exhaustion","volume":"9","author":"Sun","year":"2018","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib129","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1158\/2159-8290.CD-18-1259","article-title":"The mechanism of anti-PD-L1 antibody efficacy against PD-L1-negative tumors identifies NK cells expressing PD-L1 as a cytolytic effector","volume":"9","author":"Dong","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.pscia.2026.100109_bib130","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ebiom.2017.07.018","article-title":"The Tim-3-galectin-9 secretory pathway is involved in the immune escape of human acute myeloid leukemia cells","volume":"22","author":"Gon\u00e7alves Silva","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.pscia.2026.100109_bib131","doi-asserted-by":"crossref","DOI":"10.1177\/15330338231208846","article-title":"Research progress of immuno-inhibitory receptors in gynecological cervical cancer","volume":"22","author":"Li","year":"2023","journal-title":"Technol. Cancer Res. Treat."},{"issue":"12","key":"10.1016\/j.pscia.2026.100109_bib132","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/ijms21124362","article-title":"NKG2A\/CD94 is a new immune receptor for HLA-G and distinguishes amino acid differences in the HLA-G heavy chain","volume":"21","author":"H\u00f2","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib133","first-page":"263","article-title":"Monalizumab: inhibiting the novel immune checkpoint NKG2A","volume":"7","author":"Thorbald van Hall","year":"2019","journal-title":"J. Immunother."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib134","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1016\/j.cell.2018.10.028","article-title":"NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines","volume":"175","author":"Nadine van Montfoort","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib135","first-page":"2279","article-title":"Human leukocyte antigen (HLA)-E and HLA-F expression in gastric cancer","volume":"35","author":"Ishigami","year":"2015","journal-title":"Anticancer Res."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib136","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/ijc.28713","article-title":"Alterations in classical and nonclassical HLA expression in recurrent and progressive HPV-induced usual vulvar intraepithelial neoplasia and implications for immunotherapy","volume":"135","author":"E M G van Esch","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib137","article-title":"Comprehensive multi-omics analysis of CD36 in pan-cancers: evaluating role in prognosis, immune microenvironment, and therapeutic response","volume":"3","author":"Muhammad Sameer","year":"2025","journal-title":"PHSA"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib138","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12883-020-01640-4","article-title":"HLA-E expression in diffuse glioma: relationship with clinicopathological features and patient survival","volume":"20","author":"Wu","year":"2020","journal-title":"BMC Neurol."},{"key":"10.1016\/j.pscia.2026.100109_bib139","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2018.00267","article-title":"Acquired natural killer cell dysfunction in the tumor microenvironment of classic hodgkin lymphoma","volume":"9","author":"Chiu","year":"2018","journal-title":"Front. Immunol."},{"issue":"7749","key":"10.1016\/j.pscia.2026.100109_bib140","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib141","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib142","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/humu.21446","article-title":"Recurrence and variability of germline EPCAM deletions in Lynch syndrome","volume":"32","author":"Kuiper","year":"2011","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.pscia.2026.100109_bib143","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102614","article-title":"Novel targets for immune-checkpoint inhibition in cancer","volume":"120","author":"Borgeaud","year":"2023","journal-title":"Cancer Treat Rev."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib144","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.immuni.2015.11.005","article-title":"The inhibitory receptor NKG2A sustains virus-specific CD8+ T cells in response to a lethal poxvirus infection","volume":"43","author":"Rapaport","year":"2015","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib145","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.it.2016.10.002","article-title":"TIGIT: a key inhibitor of the cancer immunity cycle","volume":"38","author":"Manieri","year":"2017","journal-title":"Trends Immunol."},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib146","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00262-025-03947-y","article-title":"CD155 promotes the progression of colorectal cancer by restraining CD8+ T cells via the PI3K\/AKT\/NF-\u03baB pathway","volume":"74","author":"Liang","year":"2025","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib147","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12964-022-00985-2","article-title":"Bone marrow mesenchymal stem cells regulate the dysfunction of NK cells via the T cell immunoglobulin and ITIM domain in patients with myelodysplastic syndromes","volume":"20","author":"Liu","year":"2022","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib148","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/jcmm.13301","article-title":"CD155 knockdown promotes apoptosis via AKT\/Bcl-2\/Bax in colon cancer cells","volume":"22","author":"Zheng","year":"2018","journal-title":"J. Cell Mol. Med."},{"issue":"13","key":"10.1016\/j.pscia.2026.100109_bib149","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-13-3017","article-title":"Metalloprotease-mediated t.umor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30","volume":"74","author":"Schlecker","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.pscia.2026.100109_bib150","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D ligands in tumor immunity: two sides of a coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib151","article-title":"Targeted drug conjugates in cancer therapy: challenges and opportunities","volume":"2","author":"Jia","year":"2024","journal-title":"PHSA"},{"key":"10.1016\/j.pscia.2026.100109_bib152","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.810290","article-title":"The polygenic map of keloid fibroblasts reveals fibrosis-associated gene alterations in inflammation and immune responses","volume":"12","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.pscia.2026.100109_bib153","doi-asserted-by":"crossref","first-page":"5208","DOI":"10.1158\/1078-0432.CCR-09-0886","article-title":"Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B","volume":"15","author":"Paschen","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib154","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1349-7006.2012.02330.x","article-title":"Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients","volume":"103","author":"Yamaguchi","year":"2012","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib155","doi-asserted-by":"crossref","first-page":"6711","DOI":"10.4049\/jimmunol.181.10.6711","article-title":"Interaction of monocytes with NK cells upon toll-like receptor-induced expression of the NKG2D ligand MICA","volume":"181","author":"Kloss","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib156","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2035919","article-title":"MICA\/B-targeted antibody promotes NK cell-driven tumor immunity in patients with intrahepatic cholangiocarcinoma","volume":"11","author":"Oliviero","year":"2022","journal-title":"OncoImmunology"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib157","first-page":"76","article-title":"MICA\/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma","volume":"33","author":"Fang","year":"2014","journal-title":"JECCR"},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib158","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers malignant potential by regulating metallo proteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.pscia.2026.100109_bib159","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/hep.23456","article-title":"Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain a on hepatocellular carcinoma cells by down-regulating a disintegrin and metallo proteinase 9","volume":"51","author":"Kohga","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.pscia.2026.100109_bib160","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1557372","article-title":"Immune evasion by TGF-\u03b2-induced miR-183 repression of MICA\/B expression in human lung tumor cells","volume":"8","author":"Trinh","year":"2019","journal-title":"OncoImmunology"},{"key":"10.1016\/j.pscia.2026.100109_bib161","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/cmi.2014.30","article-title":"Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA\/B expression","volume":"11","author":"Xie","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2020.104379","article-title":"Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma","volume":"113","author":"Al-Abdallah","year":"2020","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.pscia.2026.100109_bib163","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/srep02739","article-title":"Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs","volume":"3","author":"Kishikawa","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pscia.2026.100109_bib164","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1158\/0008-5472.CAN-09-1688","article-title":"Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA that is shed by tumor cells in exosomes","volume":"70","author":"Ashiru","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib165","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12943-021-01492-7","article-title":"Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy","volume":"21","author":"Hosseini","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib166","doi-asserted-by":"crossref","first-page":"5455","DOI":"10.1007\/s13277-015-4313-2","article-title":"Differential expression of ligands for NKG2D and DNAM-1 receptors by epithelial ovarian cancer-derived exosomes and its influence on NK cell cytotoxicity","volume":"37","author":"Labani-Motlagh","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.pscia.2026.100109_bib167","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12951-018-0372-z","article-title":"Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-Ligand, MICA, in tetraspanin-containing nanovesicles from melanoma","volume":"16","author":"L\u00f3pez-Cobo","year":"2018","journal-title":"J. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib168","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-73712-1","article-title":"MHC class I polypeptide-related sequence B shedding modulates pancreatic tumor immunity via the activation of NKG2DLow T cells","volume":"14","author":"Toyoda","year":"2024","journal-title":"Sci. Rep."},{"issue":"6230","key":"10.1016\/j.pscia.2026.100109_bib169","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1126\/science.1258867","article-title":"A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection","volume":"348","author":"Deng","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pscia.2026.100109_bib170","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2013-01-476606","article-title":"Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity","volume":"121","author":"Reiners","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2026.100109_bib171","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1219827","article-title":"RIG-I activation induces the release of extracellular vesicles with antitumor activity","volume":"5","author":"Da\u00dfler-Plenker","year":"2016","journal-title":"OncoImmunology"},{"key":"10.1016\/j.pscia.2026.100109_bib172","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1182\/blood-2013-01-481705","article-title":"Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions","volume":"122","author":"Matta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2026.100109_bib173","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.imbio.2017.10.012","article-title":"Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy","volume":"223","author":"Gutierrez-Franco","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.pscia.2026.100109_bib174","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1158\/0008-5472.CAN-13-3017","article-title":"Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30","volume":"74","author":"Schlecker","year":"2014","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib175","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms21103726","article-title":"Mechanisms of apoptosis resistance to NK cell-mediated cytotoxicity in cancer","volume":"21","author":"Sordo-Bahamonde","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib176","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.onc.1208244","article-title":"Caspase-8 gene is frequently inactivated by the frameshift somatic mutation 1225_1226delTG in hepatocellular carcinomas","volume":"24","author":"Soung","year":"2005","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib177","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/0008-5472.815.65.3","article-title":"CASPASE-8 gene is inactivated by somatic mutations in gastric carcinomas","volume":"65","author":"Soung","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib178","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s00439-004-1129-3","article-title":"Somatic mutations of CASP3 gene in human cancers","volume":"115","author":"Soung","year":"2004","journal-title":"Hum. Genet."},{"key":"10.1016\/j.pscia.2026.100109_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2022.110257","article-title":"Anti-proliferating and apoptosis-inducing activity of chemical compound FTI-6D in association with p53 in human cancer cell lines","volume":"369","author":"Inoue","year":"2023","journal-title":"Chem. Biol. Interact."},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib180","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.364","article-title":"MicroRNA-519a-3p mediates apoptosis resistance in breast cancer cells and their escape from recognition by natural killer cells","volume":"8","author":"Breunig","year":"2017","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib181","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib182","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.molcel.2008.03.008","article-title":"IAPs: what's in a name?","volume":"30","author":"Srinivasula","year":"2008","journal-title":"Mol. Cell"},{"issue":"5302","key":"10.1016\/j.pscia.2026.100109_bib183","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1126\/science.275.5302.967","article-title":"Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype","volume":"275","author":"Rampino","year":"1997","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib184","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/s41419-018-0470-8","article-title":"Down-regulation of a pro-apoptotic pathway regulated by PCAF\/ADA3 in early stage gastric cancer","volume":"9","author":"Brasacchio","year":"2018","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib185","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1182\/blood.V96.2.594.014k36_594_600","article-title":"Impaired binding of perforin on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells","volume":"96","author":"Lehmann","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2026.100109_bib186","article-title":"Matrine induces V-ATPase-dependent cytoplasmic vacuolation and inhibits the function of the lysosome in leukemia cells","volume":"2","author":"Yang","year":"2024","journal-title":"PHSA"},{"key":"10.1016\/j.pscia.2026.100109_bib187","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10823","article-title":"Melanoma cell lysosome secretory burst neutralizes the CTL-mediated cytotoxicity at the lytic synapse","volume":"7","author":"Khazen","year":"2016","journal-title":"Nat. Commun."},{"issue":"20","key":"10.1016\/j.pscia.2026.100109_bib188","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","article-title":"Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors","volume":"98","author":"Medema","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib189","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0022645","article-title":"Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death","volume":"6","author":"de Koning","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib190","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3390\/biomedicines13030682","article-title":"Low GCNT2\/I-branching glycan expression is associated with bladder cancer aggressiveness","volume":"13","author":"Tobisawa","year":"2025","journal-title":"Biomedicines"},{"issue":"43","key":"10.1016\/j.pscia.2026.100109_bib191","doi-asserted-by":"crossref","first-page":"17450","DOI":"10.1073\/pnas.1304790110","article-title":"Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia","volume":"110","author":"Baginska","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"23","key":"10.1016\/j.pscia.2026.100109_bib192","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314608","article-title":"Preventing surgery-induced NK cell dysfunction using Anti-TGF-\u03b2 immunotherapeutics","volume":"23","author":"Market","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib193","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006238","article-title":"MUC1-C is a master regulator of MICA\/B NKG2D ligand and exosome secretion in human cancer cells","volume":"11","author":"Morimoto","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib194","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111046","article-title":"Recent progress in TGF-\u03b2 inhibitors for cancer therapy","volume":"134","author":"Huang","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.pscia.2026.100109_bib195","article-title":"Current status and research progress of oncolytic virus","volume":"2","author":"Chen","year":"2024","journal-title":"PHSA"},{"key":"10.1016\/j.pscia.2026.100109_bib196","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2025.1561102","article-title":"FAS mediates apoptosis, inflammation, and treatment of pathogen infection","volume":"15","author":"Hu","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"19","key":"10.1016\/j.pscia.2026.100109_bib197","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1038\/gt.2008.77","article-title":"Tumor cells expressing a fusion protein of MULT1 and Fas are rejected in vivo by apoptosis and NK cell activation","volume":"15","author":"Kotturi","year":"2008","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib198","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/ijc.2910570314","article-title":"Expression of APO-1 (CD95), a member of the NGF\/TNF receptor superfamily, in normal and neoplastic colon epithelium","volume":"57","author":"M\u00f6ller","year":"1994","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib199","doi-asserted-by":"crossref","first-page":"208","DOI":"10.4149\/neo_2023_221125N1132","article-title":"Bigelovin inhibits hepatocellular carcinoma cell growth and metastasis by regulating the MAPT-mediated Fas\/FasL pathway","volume":"70","author":"Wang","year":"2023","journal-title":"Neoplasma"},{"key":"10.1016\/j.pscia.2026.100109_bib200","article-title":"Functional screening of somatic mutant events in extranodal natural killer\/T-cell lymphoma with adrenal involvement","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib201","doi-asserted-by":"crossref","first-page":"170","DOI":"10.37349\/etat.2023.00128","article-title":"Cancer resistance via the downregulation of the tumor suppressors RKIP and PTEN expressions: therapeutic implications","volume":"4","author":"Moghaddam","year":"2023","journal-title":"Explor Target Antitumor Ther."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib202","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.jhep.2010.04.040","article-title":"CD95 is a key mediator of invasion and accelerated outgrowth of mouse colorectal liver metastases following radiofrequency ablation","volume":"53","author":"Nijkamp","year":"2010","journal-title":"J. Hepatol."},{"issue":"5291","key":"10.1016\/j.pscia.2026.100109_bib203","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1126\/science.274.5291.1363","article-title":"Melanoma cell expression of Fas (Apo-1\/CD95) ligand: implications for tumor immune escape","volume":"274","author":"Hahne","year":"1996","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.pscia.2026.100109_bib204","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/08923973.2025.2506696","article-title":"Kindlin-2 silencing promoted apoptosis and cell cycle arrest through the fas\/FasL pathway in hepatocellular carcinoma","volume":"47","author":"Yu","year":"2025","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib205","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1111\/j.1699-0463.1998.tb00255.x","article-title":"Immunohistochemical analysis of Fas ligand expression in sarcomas. Sarcomas express high level of FasL in vivo","volume":"106","author":"Lee","year":"1998","journal-title":"APMIS"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib206","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1038\/s41467-025-60990-0","article-title":"Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy","volume":"16","author":"Wamba","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.pscia.2026.100109_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2019.03.004","article-title":"NK cells to cure cancer","volume":"41","author":"Di Vito","year":"2019","journal-title":"Semin. Immunol."},{"issue":"7264","key":"10.1016\/j.pscia.2026.100109_bib208","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nature08402","article-title":"Membrane-bound Fas ligand only is essential for Fas-induced apoptosis","volume":"461","author":"O' Reilly","year":"2009","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.pscia.2026.100109_bib209","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3390\/cancers16172927","article-title":"Prognostic value of Fas\/Fas ligand expression on circulating tumor cells (CTCs) and immune cells in the peripheral blood of patients with metastatic breast cancer","volume":"16","author":"Papadaki","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib210","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.cellsig.2009.09.016","article-title":"Non-apoptotic Fas signaling regulates invasiveness of glioma cells and modulates MMP-2 activity via NFkappaB-TIMP-2 pathway","volume":"22","author":"Wisniewski","year":"2010","journal-title":"Cell. Signal."},{"key":"10.1016\/j.pscia.2026.100109_bib211","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2016.00504","article-title":"Manufacturing natural killer cells as medicinal products","volume":"7","author":"Chabannon","year":"2016","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib212","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.4110\/in.2020.20.e14","article-title":"NK cell-based immunotherapies in cancer","volume":"20","author":"Shin","year":"2020","journal-title":"Immune Netw."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib213","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s40425-019-0688-8","article-title":"Correction to: IL-27 enhances IL-15\/IL-18-mediated activation of human natural killer cells","volume":"7","author":"Choi","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib214","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879452","article-title":"A phase I study of locoregional high-dose autologous natural killer cell therapy with hepatic arterial infusion chemotherapy in patients with locally advanced hepatocellular carcinoma","volume":"13","author":"Bae","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.pscia.2026.100109_bib215","article-title":"Efficacy of nature killer cell combination chemotherapy for post-radical gastric cancer metastases: case report","volume":"12","author":"Yue","year":"2024","journal-title":"SAGE Open Med Case Rep"},{"key":"10.1016\/j.pscia.2026.100109_bib216","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.2147\/OTT.S201924","article-title":"Preparation of highly activated natural killer cells for advanced lung cancer therapy","volume":"12","author":"Xie","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.pscia.2026.100109_bib217","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.3389\/fimmu.2018.02041","article-title":"Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells","volume":"9","author":"Kim","year":"2018","journal-title":"Front. Immunol."},{"issue":"45","key":"10.1016\/j.pscia.2026.100109_bib218","doi-asserted-by":"crossref","first-page":"72961","DOI":"10.18632\/oncotarget.12150","article-title":"PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma","volume":"7","author":"Beldi-Ferchiou","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib219","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1038\/s41467-025-57965-6","article-title":"A protease-cleavable liposome for co-delivery of anti-PD-L1 and doxorubicin for colon cancer therapy in mice","volume":"16","author":"Liu","year":"2025","journal-title":"Nat. Commun."},{"issue":"26","key":"10.1016\/j.pscia.2026.100109_bib220","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.pscia.2026.100109_bib221","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1226720","article-title":"Therapeutic CD94\/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia","volume":"5","author":"McWilliams","year":"2016","journal-title":"OncoImmunology"},{"issue":"13","key":"10.1016\/j.pscia.2026.100109_bib222","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1182\/blood-2009-02-206532","article-title":"Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells","volume":"114","author":"Romagn\u00e9","year":"2009","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.pscia.2026.100109_bib223","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1158\/1078-0432.CCR-16-1108","article-title":"Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma","volume":"22","author":"Carlsten","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib224","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood-2013-08-519199","article-title":"Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.pscia.2026.100109_bib225","doi-asserted-by":"crossref","DOI":"10.1172\/JCI163620","article-title":"Blockade of the immunosuppressive KIR2DL5\/PVR pathway elicits potent human NK cell-mediated antitumor immunity","volume":"132","author":"Ren","year":"2022","journal-title":"J. Clin. Investig."},{"issue":"7","key":"10.1016\/j.pscia.2026.100109_bib226","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib227","doi-asserted-by":"crossref","first-page":"E32","DOI":"10.1002\/ajh.27161","article-title":"Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes","volume":"99","author":"Brunner","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"17","key":"10.1016\/j.pscia.2026.100109_bib228","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1158\/1078-0432.CCR-24-2131","article-title":"Correction: phase I\/Ib clinical trial of Sabatolimab, an anti-TIM-3 antibody, alone and in combination with Spartalizumab, an anti-PD-1 antibody, in advanced solid tumors","volume":"30","author":"Curigliano","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.pscia.2026.100109_bib229","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11912-022-01218-y","article-title":"New checkpoint inhibitors on the road: targeting TIM-3 in solid tumors","volume":"24","author":"Gomes de Morais","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.pscia.2026.100109_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115547","article-title":"Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update","volume":"225","author":"Lipson","year":"2025","journal-title":"Eur. J. Cancer"},{"issue":"13","key":"10.1016\/j.pscia.2026.100109_bib231","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1200\/JCO.24.01124","article-title":"Three-year overall survival with nivolumab plus relatlimab in advanced melanoma from RELATIVITY-047","volume":"43","author":"Tawbi","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.pscia.2026.100109_bib232","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: from bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin. Transl. Med."},{"issue":"16_suppl","key":"10.1016\/j.pscia.2026.100109_bib233","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2024.42.16_suppl.2639","article-title":"Phase 1 study of LB1410, a bivalent TIM-3\/PD-1 bispecific antibody, in patients with advanced solid tumors","volume":"42","author":"Liu","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.pscia.2026.100109_bib234","doi-asserted-by":"crossref","DOI":"10.1038\/s41551-025-01425-5","article-title":"Engineering multi-specific nano-antibodies for cancer immunotherapy","author":"Fan","year":"2025","journal-title":"Nat. Biomed. Eng."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib235","doi-asserted-by":"crossref","first-page":"6211","DOI":"10.1038\/s41467-024-50474-y","article-title":"Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.pscia.2026.100109_bib236","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/PPO.0000000000000156","article-title":"Natural killer cell adoptive transfer therapy: exploiting the first line of defense against cancer","volume":"21","author":"Davis","year":"2015","journal-title":"Cancer J."},{"key":"10.1016\/j.pscia.2026.100109_bib237","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","article-title":"Natural killer cells unleashed: checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy","volume":"31","author":"Davis","year":"2017","journal-title":"Semin. Immunol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib238","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/cancers15010117","article-title":"CAR-NK as a rapidly developed and efficient immunotherapeutic strategy against cancer","volume":"15","author":"W\u0142odarczyk","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.pscia.2026.100109_bib239","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2004-12-4797","article-title":"Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells","volume":"106","author":"Imai","year":"2005","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib240","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/aps.2017.125","article-title":"Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy","volume":"39","author":"Hu","year":"2018","journal-title":"Acta Pharmacol. Sin."},{"issue":"8","key":"10.1016\/j.pscia.2026.100109_bib241","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/s43018-023-00599-8","article-title":"Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer","volume":"4","author":"Zheng","year":"2023","journal-title":"Nat. Cancer"},{"issue":"2","key":"10.1016\/j.pscia.2026.100109_bib242","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006002","article-title":"TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells","volume":"11","author":"Bi","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.pscia.2026.100109_bib243","doi-asserted-by":"crossref","DOI":"10.1177\/09636897221094244","article-title":"Cytokine release syndrome after modified CAR-NK therapy in an advanced non-small cell lung cancer patient: a case report","volume":"31","author":"Zhang","year":"2022","journal-title":"Cell Transplant."},{"issue":"17","key":"10.1016\/j.pscia.2026.100109_bib244","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.3390\/cancers14174229","article-title":"Safety and efficacy of allogeneic natural killer cells in combination with pembrolizumab in patients with chemotherapy-refractory biliary tract cancer: a multicenter open-label phase 1\/2a trial","volume":"14","author":"Leem","year":"2022","journal-title":"Cancers (Basel)"}],"updated-by":[{"DOI":"10.1016\/j.pscia.2026.100141","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000024?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000024?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T09:59:10Z","timestamp":1772186350000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216926000024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":245,"alternative-id":["S2773216926000024"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100109","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of tumor cell evasion from NK cell-mediated killing and advances in NK cell-based cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100109","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100109"}}